TP53 and myelodysplastic syndrome: APR-246 is currently being evaluated in clinical trials to explore therapeutic effects in acute myeloid leukemia and myelodysplastic syndrome with p53 mutations, where it can bind to mutant p53 in leukemic cells to restore its activity (17, 18).